Abstract
Opicapone (OPC) proved to be effective in treating end-of-dose motor fluctuations (MF) in Parkinson's disease (PD) patients. The OPTIPARK study evaluated OPC 50 mg in a heterogeneous population of PD patients treated in real-world conditions. We evaluated the effectiveness of OPC in PD patients with MF according to baseline use of entacapone (ENT).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
